Health Technology

​

BCM is the home of advanced organ repair and replacement with the patient’s own DNA. Our Autologous Regenerative Tissue Replacement (ARTR™) organ repair technology is based on the 5StageAutograft™ procedure. A biopsy of the patient’s failing organ is the starting point. The harvested cells are reconditioned and grown on organic bedding (“scaffolding”). These new cells are grown in this tissue structure to the specifications of the surgeon.

​

When ready, that tissue structure is surgically inserted into the patient’s failing organ where the new cells integrate with the other cells and rapidly multiply. As this cell regeneration process proceeds the patient’s organ transitions to a healthy state. This organ repair process has completed stage one clinical trials on 8 kidney patients. Further clinical trials are scheduled for kidneys and the process is to be expanded to include the liver, lungs, and pancreas.

​

The next generation of this process is already in development under the name ARTR™ Plus+, enabling the growth of complete lab-based autologous replacement organs. In this transplant procedure, in parallel with the acquisition of the patient’s cells and the growth of the new cells, a same-sized organ from a deceased donor provides the structure. Just a size match suffices, no blood type or other criteria matter. The donated organ is sterilized at the cellular level, to remove all DNA from the donor. A completely sterilized organ structure is the result.

​

The newly grown autologous cells are now embedded into the sterilized organ and the reconstituted organ is used to replace the patient’s failing organ in a conventional organ transplant surgery. In all these ARTR™ procedures no follow-on anti-rejection drugs are required. To learn more, see the videos below or contact a BCM representative.

​

​